Published in Postgrad Med J on December 01, 1983
Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J (1991) 0.92
Effects of prostaglandins and COX-inhibiting drugs on skeletal muscle adaptations to exercise. J Appl Physiol (1985) (2013) 0.87
Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. Cancer Prev Res (Phila) (2016) 0.76
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
On the nature of inhibition in the intestine. J Physiol (1930) 20.47
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
THE USE OF ISOLATED ORGANS FOR DETECTING ACTIVE SUBSTANCES IN THE CIRCULATING BLOOD. Br J Pharmacol Chemother (1964) 9.77
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90
Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol (1971) 7.75
The technique of superfusion. Br J Pharmacol Chemother (1953) 6.81
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
The release of prostaglandins from lung and other tissues. Ann N Y Acad Sci (1971) 4.91
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A (1977) 3.74
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Parallel assay of prostaglandin-like activity in rat inflammatory exudate by means of cascade superfusion. J Pharm Pharmacol (1969) 3.59
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
Effect of pyrogen and antipyretics on prostaglandin acitvity in cisternal c.s.f. of unanaesthetized cats. J Physiol (1973) 3.13
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
The occurrence of prostaglandin E2 in splenic venous blood of the dog following splenic nerve stimulation. Br J Pharmacol Chemother (1968) 2.47
Localisation and stimulation of prostacyclin production in vascular cells. Nature (1978) 2.45
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother (1967) 2.44
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Conversion of angiotensin I to angiotensin II. Nature (1967) 2.26
Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature (1978) 2.10
Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol (1982) 2.01
The release of catechol amines from the adrenal medulla by histamine. Br J Pharmacol Chemother (1965) 2.00
Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet (1982) 1.97
Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3',5'-cyclic monophosphate and protein kinase. Biochim Biophys Acta (1977) 1.97
Fate of angiotensin I in the circulation. Nature (1968) 1.94
Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet (1983) 1.94
Selective passage of prostaglandins across the lung. Nature (1969) 1.92
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
The detection and estimation of bradykinin in the circulating blood. Br J Pharmacol Chemother (1967) 1.80
The effects of alteration of blood-volume on the concentration of circulating angiotensin in anaesthetized dogs. J Physiol (1966) 1.66
Cyclic adenosine 3',5'-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. J Clin Invest (1977) 1.63
Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa. Nature (1981) 1.62
Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathol Microbiol Scand (1952) 1.61
Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease. Surgery (1980) 1.61
Release of catecholamines in the guinea-pig by substances involved in anaphylaxis. Nature (1967) 1.59
Prostacyclin: a potent antimetastatic agent. Science (1981) 1.58
Cyclic adenosine 3',5'-monophosphate and prostacyclin inhibit membrane phospholipase activity in platelets. Biochem Biophys Res Commun (1977) 1.56
PROSTAGLANDINS AND RELATED FACTORS. 28. METABOLISM OF PROSTAGLANDIN E1 IN GUINEA PIG LUNG: THE STRUCTURES OF TWO METABOLITES. J Biol Chem (1964) 1.56
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins (1976) 1.56
Cardiac and renal prostaglandin I2. Biosynthesis and biological effects in isolated perfused rabbit tissues. J Clin Invest (1978) 1.48
Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol (1979) 1.47
The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol (1966) 1.41
Dependency of renal blood flow on prostaglandin synthesis in the dog. Circ Res (1973) 1.37
Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta (1978) 1.37
Role of Ca2+ and cyclic AMP in the regulation of the production of prostacyclin by the vascular endothelium. Proc Natl Acad Sci U S A (1982) 1.36
A laminar flow superfusion technique with much increased sensitivity for the detection of smooth muscle-stimulating substances. Eur J Pharmacol (1976) 1.29
Prostacyclin deficiency in thrombotic thrombocytopenic purpura. Lancet (1979) 1.27
Disappearance of angiotensin from the circulation of the dog. Nature (1967) 1.25
Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med (1980) 1.24
Prostaglandin endoperoxides IX. Characterization of rabbit aorta contracting substance (RCS) from guinea pig lung and human platelets. Acta Physiol Scand (1975) 1.21
Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet (1980) 1.18
Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet (1980) 1.18
Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol (1982) 1.17
The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin (dicumarol). Vasc Dis (1968) 1.17
Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Lancet (1981) 1.14
The release of catecholamines from the adrenal medulla by peptides. Br J Pharmacol Chemother (1967) 1.14
Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin. J Clin Invest (1981) 1.12
Effect of prostacyclin (PGI2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins (1978) 1.11
Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets. Biochem Biophys Res Commun (1976) 1.10
The inactivation of noradrenaline and isoprenaline in dogs. Br J Pharmacol (1970) 1.09
Release of prostaglandins from embolized lungs. Br J Surg (1970) 1.06
The estimation of catecholamines by biological assay. Pharmacol Rev (1966) 1.06
Recirculation of prostacyclin (PGI2) in the dog. Br J Pharmacol (1978) 1.06
Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet (1983) 1.06
Prostacyclin therapy of thrombotic thrombocytopenic purpura. Lancet (1980) 1.05
The generation of kinins in the blood of dogs during hypotension due to haemorrhage. Clin Sci (1970) 1.04
Treatment of pulmonary embolism with prostacyclin. Surgery (1980) 1.04
Prostacyclin generation in atherosclerotic arteries. Lancet (1979) 1.04
Prostacyclin in experimental myocardial ischemia: effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol (1981) 1.03
Contribution of intrarenal generation of prostaglandin to autoregulation of renal blood flow in the dog. Circ Res (1973) 1.03
Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. Am J Physiol (1980) 1.02
Successful treatment of Raynaud's Syndrome with prostacyclin. Thromb Haemost (1981) 1.00
Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins (1979) 0.98
Disappearance of catecholamines from the circulation. Nature (1968) 0.98
Prostacyclin for pulmonary hypertension. Lancet (1980) 0.98
The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time. Thromb Haemost (1979) 0.98
Metabolism of prostacyclin. Oxidation by rhesus monkey lung 15-hydroxyl prostaglandin dehydrogenase. Arch Biochem Biophys (1978) 0.97
Differential inhibition by prostaglandins of the renal actions of pressor stimuli. Prostaglandins (1973) 0.97
The effect of prostacyclin infusion on endotoxin-induced lung injury. Surgery (1981) 0.96
Bioassay of prostaglandins and biologically active substances derived from arachidonic acid. Adv Prostaglandin Thromboxane Res (1978) 0.96
Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia. J Pharmacol Exp Ther (1981) 0.94
Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men. Pharmacol Res Commun (1978) 0.94
Twenty-four- and 48-hour canine liver preservation by simple hypothermia with prostacyclin. Ann Surg (1982) 0.93
Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemost (1978) 0.92
Prostacyclin administration during cardiopulmonary bypass in man. Lancet (1981) 0.92
Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol (1982) 0.88
The effect of peroxidized arachidonic acid upon human platelet aggregation. Lipids (1974) 0.88
Measurement of epinephrine, norepinephrine and related compounds; bioassay procedures. Pharmacol Rev (1959) 0.88
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90
Prostaglandins released by the spleen. Nature (1968) 7.61
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54
Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1972) 2.52
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Prostaglandins, oxygen tension and smooth muscle tone. Br J Pharmacol (1972) 2.51
Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther (1973) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother (1967) 2.44
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
Phospholipase A2 activity of guinea-pig isolated perfused lungs: stimulation, and inhibition by anti-inflammatory steroids. Br J Pharmacol (1978) 2.41
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A (1995) 2.36
The contribution of prostaglandin production to contractions of the isolated uterus of the rat. Br J Pharmacol (1973) 2.33
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Conversion of angiotensin I to angiotensin II. Nature (1967) 2.26
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24
Release of prostaglandin E-1 from the rat stomach. Nature (1967) 2.13
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A (1989) 2.08
Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07
The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06
The release of catechol amines from the adrenal medulla by histamine. Br J Pharmacol Chemother (1965) 2.00
Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A (1993) 1.96
Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol (1989) 1.95
Fate of angiotensin I in the circulation. Nature (1968) 1.94
Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun (1990) 1.94
Metabolism of the angiotensins in isolated perfused tissues. Nature (1969) 1.91
5-hydroxytryptamine in the circulation of the dog. Nature (1967) 1.88
The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Pharmacol (1977) 1.87
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins (1978) 1.85
Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol (1978) 1.85
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Proceedings: Prostaglandin generation maintains the smooth muscle tone of the rabbit isolated jejunum. Br J Pharmacol (1972) 1.80
The detection and estimation of bradykinin in the circulating blood. Br J Pharmacol Chemother (1967) 1.80
Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U S A (1987) 1.80
The effects of alteration of blood-volume on the concentration of circulating angiotensin in anaesthetized dogs. J Physiol (1966) 1.66
Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids. Nature (1976) 1.65
The generation from arachidonic acid of rabbit aorta contracting substance (RCS) by a microsomal enzyme preparation which also generates prostaglandins. Br J Pharmacol (1972) 1.65
Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol (1995) 1.63
Prostacyclin is a circulating hormone. Nature (1978) 1.60
Synthesis of 6-keto-PGF1alpha by ram seminal vesicle microsomes. Prostaglandins (1977) 1.57
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins (1976) 1.56
The mode of action of aspirin and similar compounds. J Allergy Clin Immunol (1976) 1.52
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci U S A (1997) 1.52
Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A (1988) 1.51
Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol (1993) 1.51
Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature (1970) 1.51
Eicosanoids in inflammation. Ann Clin Res (1984) 1.50
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A (1991) 1.50
Prostaglandins as mediators of inflammation. Adv Prostaglandin Thromboxane Res (1976) 1.48
Rapid reduction of prostaglandin 15-hydroxy dehydrogenase activity in rat tissues after treatment with protein synthesis inhibitors. Br J Pharmacol (1975) 1.48
The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. Eur J Pharmacol (1980) 1.48
Some effects of inhibiting endogenous prostaglandin formation on the responses of the cat spleen. Br J Pharmacol (1973) 1.47
Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol (1989) 1.45
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. Proc Natl Acad Sci U S A (1990) 1.43
Genetic hypertension in rats is accompanied by a defect in renal prostaglandin catabolism. Nature (1976) 1.41
The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol (1966) 1.41
Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol (1993) 1.40
Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins (1976) 1.40
Actions of prostacyclin (PGI2) and its product, 6-oxo-PGF1alpha on the rat gastric mucosa in vivo and in vitro. Prostaglandins (1978) 1.39
Mediators produced by the endothelial cell. Hypertension (1988) 1.38
The release of rabbit aorta contracting substance (RCS) from chopped lung and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1970) 1.38
Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta (1978) 1.37
The effects of antiinflammatory drugs on the production of prostaglandins in vivo. Adv Prostaglandin Thromboxane Res (1976) 1.36
Inhibition of prostaglandin biosynthesis. Biochem Pharmacol (1974) 1.34
Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci U S A (1999) 1.34
Inhibition of prostaglandin biosynthesis as the mechanism of analgesia of aspirin-like drugs in the dog knee joint. Eur J Pharmacol (1975) 1.34
Prostaglandin production contributes to the contractions of the rat isolated uterus. Br J Pharmacol (1972) 1.33
Effects of gastrin and its analogues on isolated smooth muscles. Nature (1967) 1.32
Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci U S A (2000) 1.32
Mode of action of aspirin-like drugs. Adv Intern Med (1979) 1.30
Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res (1993) 1.29
Prostaglandin production by rabbit isolated jejunum and its relationship to the inherent tone of the preparation. Br J Pharmacol (1976) 1.29